Blood substitute beneficial for trauma patients:
This article was originally published in Clinica
Executive Summary
Northfield Laboratories' oxygen-carrying blood substitute PolyHeme improves survival rates in trauma situations where blood might not be available, the company told the US Health and Human Services Advisory Committee on Blood Safety and Availability. In an assessment of 53 patients, none of whom received blood from a blood bank during the study, 85% survived after infusions of the modified haemoglobin, essentially the same percentage that would have been expected to survive if banked blood had been used, said the Evanston Illinois-based company. PolyHeme is undergoing trials for both trauma and surgery.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.